Prostate cancer trials recruiting in Massachusetts

All Prostate cancer trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
  NCT05899361 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06879041 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT07719361 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Plymouth
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
  NCT03460977 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Newton
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
  NCT06844383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT07244341 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston, Newton
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06067841 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
  NCT07192614 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
  NCT07336446 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
  NCT06579417 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
  NCT07206056 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Massachusetts: Boston
• Androgen-responsive POSLUMA-guided Intra-prostatic Boost
  NCT07393867 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston, Milford, Weymouth
• Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
  NCT06496256 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• CV CARE: CardioVascular Care in PC Patients
  NCT06202820 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Clinical Trial of Approaches to Prostate Cancer Surgery
  NCT05155501 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 80 Years · Sex: Male · Massachusetts: Boston
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Massachusetts: Jamaica Plain
• Comprehensive Outcomes for After Cancer Health
  NCT05349227 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
  NCT05804318 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
  NCT06040125 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Distance-Based Exercise to Preserve Function and Prevent Disability
  NCT07059884 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
  NCT06239194 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
  NCT05488548 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
  NCT04373564 · Phase: Phase 4 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Massachusetts: Boston, Methuen, Worcester
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
  NCT05918263 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
  NCT05327465 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
  NCT06862856 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
  NCT06517901 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Massachusetts: Burlington
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
  NCT04812366 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
  NCT07569926 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
  NCT05463796 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Massachusetts: Boston
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · Massachusetts: Holyoke
• International Registry for Men With Advanced Prostate Cancer (IRONMAN)
  NCT03151629 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Massachusetts: Boston, Worcester
• Jump: MR Simulation For Radiation Therapy Master Protocol
  NCT04545957 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• MRI Guided Prostate Biopsy
  NCT06302595 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years and older · Sex: Male · Massachusetts: Boston
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Massachusetts: Boston
• PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
  NCT06274047 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06801236 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
  NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
  NCT07006727 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Massachusetts: Boston
• Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
  NCT04946370 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
  NCT06062745 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
  NCT06099093 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
  NCT06398639 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 69 Years · Sex: Male · Massachusetts: Boston
• Precision-Based Genomics in Prostate Cancer
  NCT04706663 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: Male · Massachusetts: Boston
• Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
  NCT06957691 · Phase: Phase 2 · Ages: 40 Years and older · Sex: Male · Massachusetts: Boston
• Prostate Active Surveillance Study
  NCT00756665 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Massachusetts: Boston
• Prostate Cancer Genetic Risk Evaluation and Screening Study
  NCT05129605 · Phase: Not specified · Ages: 35 Years to 74 Years · Sex: Male · Massachusetts: Boston
• Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
  NCT04472338 · Phase: Not specified · Ages: 40 Years and older · Sex: Male · Massachusetts: Boston
• RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
  NCT05765500 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston, Foxborough
• Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
  NCT07427043 · Phase: Phase 3 · Ages: 45 Years and older · Sex: Male · Massachusetts: Boston
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Massachusetts: Worcester
• Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
  NCT04363164 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · Massachusetts: Boston
• Serial MRI Scans During Radiation Therapy
  NCT04188535 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Burlington
• Stereotactic Magnetic Resonance Guided Radiation Therapy
  NCT04115254 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
  NCT06855277 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Massachusetts: Boston
• Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
  NCT06549465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
  NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
  NCT07181161 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: Male · Massachusetts: Boston
• Study of AZD0754 in Participants With Metastatic Prostate Cancer
  NCT06267729 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: Male · Massachusetts: Boston
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
  NCT05417594 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Massachusetts: Boston
• Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
  NCT04890613 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
  NCT06966024 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Massachusetts: Boston
• Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
  NCT06800313 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Foxborough, Methuen, Milford
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston, Milford, South Weymouth
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Burlington, Peabody, Springfield, Winchester
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Massachusetts: Boston
• The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
  NCT05926102 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 69 Years · Sex: Male · Massachusetts: Boston
• This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
  NCT06451497 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
  NCT04787744 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · Massachusetts: Boston
• Video Education With Result Dependent dIsclosure
  NCT05225428 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston